KRAS and colorectal carcinoma: When overall survival rates at 60 months were compared among NRAS‐mutation(+), KRAS‐mutation(+), and oncogene‐mutation(−) groups, NRAS‐mutation(+) and oncogene‐mutation(−) CRC also showed better survival rates than KRAS‐mutation(+) CRC (P = 0.02, chi‐square test) (Table 2).